BerGenBio

Investor Presentation • Jan 12, 2021

BERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES

BERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES

Bergen, Norway, 12[th] January 2021 - BerGenBio ASA (OSE:BGBIO), a clinical

-stage biopharmaceutical company developing novel, selective AXL kinase

inhibitors for severe unmet medical need, is pleased to announce that a member

of the senior management team is presenting at the following virtual

conferences:

Solebury Trout Management Access Event, 6-15 January 2021

Register for the event

here (https://troutaccess.com/investor.php/contact/mailcheck/hash/566554ad12a903f

0f24683765aa9ed77)

Presentation available via

platform (https://troutaccess.com/investor.php/participatingcompanies/details/com

pany_hash/408bc6e8553a9de9a16f78dce09fd04f/conference_hash/566554ad12a903f0f24683

765aa9ed77)

H.C. Wainwright Bioconnect 2021, 11-14 January 2021

Register for the event here (https://hcwevents.com/bioconnect/#toggle-id-4

-closed) to access presentation

SEB Virtual Nordic Healthcare Conference, 18 January 2021

Live presentation at 9:40am CET on 18 January

All presentations will be made available on the Company website:

www.bergenbio.com/investors/presentations/

- END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the

biological mechanisms underlying life-threatening diseases. In cancer, AXL

suppresses the body's immune response to tumours and drives cancer treatment

failure across many indications. AXL expression defines a very poor prognosis

subgroup in most cancers. AXL inhibitors, therefore, have potential high value

at the centre of cancer combination therapy, addressing significant unmet

medical needs and multiple high-value market opportunities. Research has also

shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class

selective AXL inhibitor in a broad phase II clinical development programme.

Ongoing clinical trials are investigating bemcentinib in multiple solid and

haematological tumours, in combination with current and emerging therapies

(including immunotherapies, targeted therapies and chemotherapy), and as a

single agent. Bemcentinib targets and binds to the intracellular catalytic

kinase domain of AXL receptor tyrosine kinase and inhibits its activity.

Increase in AXL function has been linked to key mechanisms of drug resistance

and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II oncology clinical development

programme focused on combination and single agent therapy in lung cancer,

leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,

tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is

developing companion diagnostic tests to identify patient populations most

likely to benefit from bemcentinib: this is expected to facilitate more

efficient registration trials supporting a precision medicine-based

commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.